Overview
Becton, Dickinson and Company (BD) is a global medical-technology company that develops and supplies medical devices, laboratory equipment and diagnostic products. Its products support medication delivery and management, infection prevention, diagnostic testing, surgical and interventional care, and life-sciences research. BD’s stated purpose is “advancing the world of health.” [1][2] Its current business areas are Medical Essentials, Connected Care, BioPharma Systems and Interventional.[3][2]
BD reported FY2025 revenue of $21.840 billion. That figure includes its former Life Sciences segment, which was spun off in February 2026.[4][5] The company describes itself as serving more than 190 countries and territories, with over 60,000 employees or associates.[2][6] [1][3][4][5][2][6]
Products & services
Becton, Dickinson and Company (BD) offers products across medical technology, life sciences and interventional care. Its medical products include IV catheters and central lines, vascular-access ultrasound, flush syringes, infusion connectors, syringes and needles; infusion pumps and disposables; medication-dispensing and pharmacy-automation systems; prefillable drug-delivery systems; and patient-monitoring products such as hemodynamic monitors, tissue-oximetry monitors and pulmonary-artery catheters. Its life-sciences portfolio includes blood- and TB-culture systems, organism-identification and drug-susceptibility systems, microbiology automation, molecular-testing platforms, cell sorters and analyzers, research reagents, and specimen-collection and transport products. Interventional products include surgical-repair materials, antimicrobial irrigation and skin-preparation products, angioplasty balloons, ablation catheters, vascular stents, biopsy and thrombectomy products, and urology and urine-management devices.[7][8][9][10][11][12]
Named examples include the BD Alaris™ integrated infusion system, which combines infusion pumps and related modules with software; the BD MAX™ automated molecular-testing platform, which combines nucleic-acid extraction and real-time PCR and can process up to 24 samples; the BD Pyxis™ automated medication-dispensing portfolio; and the BD BACTEC™ blood-culture system, which uses fluorescence detection. Other products include BD Vacutainer® specimen-collection products, BD ChloraPrep™ skin preparation, and the PureWick™ urine-collection system. BD also offers technical and regulatory support and combination-product testing for drug-delivery systems, along with implementation guidance, training and troubleshooting for medication-management technology.[13][14][15][16][17][18][19][20][21][7]
For fiscal 2025, BD reported revenue of $21.840 billion: Medical generated $11.456 billion (about 52.5%), Life Sciences $5.167 billion (about 23.7%), and Interventional $5.217 billion (about 23.9%). These figures reflect the segment structure reported for FY2025.[22] [7][8][9][10][11][12][13][22][14][15][16][17][18][19][20][21]
Geographic presence
BD’s FY2025 revenue was $21.84 billion. By reported geography, revenue was $12.79 billion in the United States (about 58.6%), $4.73 billion in EMEA (21.7%), $3.09 billion in Greater Asia (14.2%), and $1.23 billion in Other (5.6%). The company defines Other as Latin America and Canada, and its United States figures include Puerto Rico; these disclosures provide regional rather than country-level revenue.[23][24]
BD manufactures worldwide. Its FY2025 filing lists non-U.S. manufacturing operations in Bosnia and Herzegovina, Brazil, Canada, China, the Dominican Republic, France, Germany, Hungary, India, Ireland, Japan, Malaysia, Mexico, the Netherlands, Singapore, Spain, Switzerland and the United Kingdom. At September 30, 2025, BD owned or leased 290 facilities totaling about 26.1 million square feet; 12.45 million square feet were in the United States, including Puerto Rico, and 13.64 million were international. Sales offices and distribution centers are also located worldwide.[25][26]
BD identifies enterprise R&D centers of excellence in the United States, India, China, Singapore and Ireland. It reports that most R&D takes place in North America, with significant additional activity in Greater Asia and Europe. The principal executive offices are in Franklin Lakes, New Jersey. BD reported approximately 72,000 associates in 61 countries as of September 30, 2025, without disclosing a regional headcount breakdown.[27][28][29] [23][24][25][26][27][28][29]
Business segments
BD’s FY2026 reporting reflects a reorganization effective October 1, 2025. After the February 2026 separation of Biosciences and Diagnostic Solutions, its four continuing reportable segments are Medical Essentials, Connected Care, BioPharma Systems, and Interventional.[3][30] In BD’s organizational mapping, Medical Essentials covers Medication Delivery Solutions and Specimen Management; Connected Care covers Medication Management Solutions and Advanced Patient Monitoring; BioPharma Systems includes BioPharma Systems, formerly Pharmaceutical Systems; and Interventional includes Peripheral Intervention, Urology and Critical Care, and Surgery.[31]
For the nine months ended June 30, 2026, the segments contributed approximately 34.7% of continuing-operations revenue for Medical Essentials ($4.918 billion), 24.5% for Connected Care ($3.475 billion), 11.9% for BioPharma Systems ($1.689 billion), and 28.9% for Interventional ($4.101 billion), calculated against total continuing-operations revenue of $14.183 billion. These are FY2026 year-to-date shares, not full-year figures.[32][33] BD’s FY2025 annual segment figures use its former three-segment structure, so they are not directly comparable with this current breakdown.[34][35][36][37] [3][30][31][32][33][34][35][36][37]
Company history
Becton, Dickinson & Co. was founded in 1897 by Maxwell W. Becton and Fairleigh S. Dickinson; its first sale was an all-glass syringe. The company opened a syringe-and-needle factory in 1906, introduced a specialized insulin syringe in 1924, launched Vacutainer blood-collection tubes in 1949, and introduced its Plastipak disposable plastic syringe in 1961.[38][39][40] The company held its initial public offering on April 23, 1962.[41]
BD expanded through its 2015 acquisition of CareFusion and its 2017 acquisition of C. R. Bard.[42][43] In 2022, it completed the spin-off of its diabetes-care business as embecta; in 2026, it completed the separation and combination of its Biosciences & Diagnostic Solutions business with Waters Corporation.[44][45] [38][39][40][41][42][43][44][45]
Sources
- BECTON DICKINSON & CO — Full financial report (2025 Y)
- www.bd.com[2]
- BECTON DICKINSON & CO — Full financial report (2026 Q 3)
- jobs.bd.com[6]
- www.bd.com[14]
- www.bd.com[15]
- www.bd.com[16]
- go.bd.com[17]
- www.bd.com[18]
- www.bd.com[19]
- www.bd.com[20]
- www.bd.com[21]
- BECTON DICKINSON & CO — Presentation (2026 Q 3)[30]
- go.bd.com[38]
- news.bd.com[39]
- news.bd.com[40]
- investors.bd.com[41]
- investors.bd.com[42]
- investors.bd.com[43]
- investors.bd.com[44]
- investors.bd.com[45]
Continue your research
From company context to financial detail.
Explore original sources and worldwide fundamental financial data and intelligence with Finbar.
Explore BECTON DICKINSON & CO in Finbar ↗